Calprotectin as a companion biomarker for colorectal cancer: A lesson from microscopic bowel inflammation
- PMID: 36973068
- DOI: 10.1111/1756-185X.14677
Calprotectin as a companion biomarker for colorectal cancer: A lesson from microscopic bowel inflammation
Comment on
-
Fecal calprotectin as a biomarker of microscopic bowel inflammation in patients with spondyloarthritis.Int J Rheum Dis. 2022 Sep;25(9):1078-1086. doi: 10.1111/1756-185X.14388. Epub 2022 Jul 18. Int J Rheum Dis. 2022. PMID: 35855677
References
REFERENCES
-
- Campos JF, Resende GG, Barbosa AJA, et al. Fecal calprotectin as a biomarker of microscopic bowel inflammation in patients with spondyloarthritis. Int J Rheum Dis. 2022;25(9):1078-1086.
-
- Wang S, Tsou HK, Chiou JY, Wang YH, Zhang Z, Wei JC. Increased risk of inflammatory bowel disease among patients with ankylosing spondylitis: a 13-year population-based cohort study. Front Immunol. 2020;11:578732.
-
- Huang JX, Lee YH, Ko MY, Wei JC. Calprotectin in psoriatic arthritis: inflammation and beyond. Int J Rheum Dis. 2023;26(1):11-12.
-
- Benson AB 3rd, Kiss I, Bridgewater J, et al. BATON-CRC: a phase II randomized trial comparing tivozanib plus mFOLFOX6 with bevacizumab plus mFOLFOX6 in stage IV metastatic colorectal cancer. Clin Cancer Res. 2016;22(20):5058-5067.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
